The Latest Cardiac and Vascular News
DUBLIN – July 31, 2017 – Medtronic plc (NYSE:MDT) today announced CE (Conformité Européenne) mark and European launch of the CoreValve(TM)Evolut(TM) PRO valve for the treatment of severe aortic stenosis for symptomatic patients who are at intermediate, high or extreme risk for open heart surgery. Clinical data for the Evolut PRO valve […]
DUBLIN, Ohio, July 30, 2017 /PRNewswire/ — Cardinal Health (NYSE: CAH) today announced that it has completed the acquisition of Medtronic’s Patient Care, Deep Vein Thrombosis and Nutritional Insufficiency business for $6.1 billion. The acquisition was funded with a combination of $4.5 billion in new senior unsecured notes, existing cash and borrowings under our existing credit […]
BRAMPTON, Ontario, July 26, 2017 (GLOBE NEWSWIRE) — Medtronic Canada, a subsidiary of Medtronic plc, today announced it has received a Health Canada licence and is launching its first and only magnetic resonance imaging (MRI) conditional cardiac resynchronization therapy defibrillators (CRT-Ds) for heart failure. Heart failure causes or contributes to […]
EDEN PRAIRIE, Minn.–(BUSINESS WIRE)–Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies, today announced it has received an investigational device exemption (IDE) from the U.S. Food and Drug Administration (FDA) to initiate a pivotal clinical trial of the SurVeil™ drug-coated balloon (DCB). The randomized […]
Press Release DUBLIN – July 11, 2017 – Medtronic plc (NYSE: MDT) today announced first enrollments in the STOP AF First clinical trial. The trial will evaluate the safety and effectiveness of performing pulmonary vein isolation (PVI) with the Arctic Front Advance(TM) Cryoballoon in patients with symptomatic paroxysmal atrial fibrillation (AF) prior […]
Press Release DUBLIN – July 10, 2017 – Medtronic plc (NYSE: MDT) today announced the expanded U.S. Food and Drug Administration (FDA) approval of the self-expanding CoreValve(TM) Evolut(TM) transcatheter aortic valve replacement (TAVR) platform to include patients with symptomatic severe aortic stenosis who are at an intermediate risk for open-heart surgery. […]
DUBLIN – July 10, 2017 – Medtronic plc (NYSE: MDT) today announced the expanded U.S. Food and Drug Administration (FDA) approval of the self-expanding CoreValve(TM) Evolut(TM) transcatheter aortic valve replacement (TAVR) platform to include patients with symptomatic severe aortic stenosis who are at an intermediate risk for open-heart surgery. With hemodynamic […]
Medtronic will add Onyx to the Resolute stents available in Japan (Integrity has been selling there since 2012). Resolute Onyx drug-eluting stent launches in Japan JULY 7, 2017 BY SARAH FAULKNER Medtronic (NYSE:MDT) said this week that it’s Resolute Onyx drug-eluting stent will launch in Japan on July 10th. The drug-eluting stent has […]
DUBLIN and VIENNA – June 20, 2017 – Medtronic plc (NSYE: MDT) Medtronic Press Release: today announced new data showing that use of its cardiac resynchronization therapy (CRT) devices – with its proprietary AdaptivCRT(TM) and EffectiveCRT(TM) algorithms – results in lower healthcare system costs, and improves therapy delivery in heart […]
Nsadaq GlobeNewswire DUBLIN and VIENNA – June 18, 2017 – Continuing its leadership in the detection, reduction, and treatment of atrial fibrillation (AF), Medtronic plc (NYSE: MDT) today announced that its Reactive ATP(TM) therapy slows the progression of AF in patients with implanted cardiac devices. A robust, real-world analysis of […]
